Merck Wards Off More Januvia Infringers In India
This article was originally published in PharmAsia News
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export two of its diabetes therapies, or hope to introduce copies of these on the domestic market, infringing on its patents.
You may also be interested in...
Alleged infringers of the patent on remogliflozin are facing legal heat in India from Glenmark, in an ongoing case where copies of the product were apparently offered for sale including via third-party trading sites.
Merck & Co has sought to block Jubilant Life Sciences over the alleged infringement of its patent on Januvia (sitagliptin) in India, continuing with a string of IPR-related legal action in the country.
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.